RE: Trading Update!31 Jan 2023 10:05
Super well run company with niche sector in defensive healthcare market segment. I do not want to see any move to NASDAQ for at least 3 or 4 years. I want the company to carry on exactly as they are doing, expanding and developing new markets and growing by 25% each year to achieve solid profitability. By all means draw up the expansion plan to meet the next level (s) of demand, but let the plan be carried out by a larger pharma company seeking to move into this segment. For me it is a question of when not if, and the longer it takes the higher the takeover price. In the shorter term I can see more micro cap institution funds adding TRX to their portfolios.